(Q46638001)

23 December 2017

title

Adjuvant aromatase inhibitors for breast cancer (English)

1 reference

23 December 2017

author

Anthony Howell

series ordinal

1

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

23 December 2017

published in

The Lancet

1 reference

23 December 2017

volume

366

1 reference

23 December 2017

issue

9484

1 reference

23 December 2017

page(s)

431-433

1 reference

23 December 2017

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Aromatase inhibitors: future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967036-5

7 January 2021

10.1016/S0140-6736(05)67036-5

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017